GFM
ZVRA icon

GF Fund Management’s Zevra Therapeutics ZVRA Stock Holding History

GF Fund Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Sell
1,194
-62
-5% -$689 ﹤0.01% 496
2026
Q1 		$11.7K Buy
1,256
+150
+14% +$1.35K ﹤0.01% 546
2025
Q4 		$9.91K Sell
1,106
-102
-8% -$965 ﹤0.01% 575
2025
Q3 		$11.5K Sell
1,208
-159
-12% -$1.59K ﹤0.01% 544
2025
Q2 		$12K Hold
1,367
– – ﹤0.01% 546
2025
Q1 		$10.2K Buy
1,367
+246
+22% +$1.96K ﹤0.01% 560
2024
Q4 		$9.35K Buy
+1,121
New +$9.57K ﹤0.01% 555

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GF Fund Management's ZVRA Position: Q2 2026 in Review

GF Fund Management reduced its Zevra Therapeutics (ZVRA) stake by 4.9% in Q2 2026, selling an estimated $689 and leaving 1,194 shares worth $17.1K. The position accounts for ﹤0.01% of the portfolio, ranked #496.

GF Fund Management first reported a position in ZVRA in Q4 2024 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • GF Fund Management held 1,194 shares of Zevra Therapeutics worth $17.1K as of Q2 2026.
  • GF Fund Management sold 62 Zevra Therapeutics shares in Q2 2026, an estimated $689.
  • Zevra Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #496 holding.
  • GF Fund Management first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.